Abstract Background Primary Human Papilloma Virus (HPV) testing is the currently
recommended cervical cancer (CxCa) screening strategy by the Portuguese Society of …

Background HPV test appears to be more effective in cervical cancer (CC) screening.
However, the decision of its adoption as a primary screening method by substituting the …

Background HPV cervical cancer screening (CCS) must use validated HPV tests based on
the molecular detection of either viral mRNA (Aptima HPV Assay—AHPV) or DNA. AHPV …

Please cite this paper as: van Rosmalen J, de Kok I, van Ballegooijen M. Cost‐effectiveness
of cervical cancer screening: cytology versus human papillomavirus DNA testing. BJOG …

Objectives In England, human papillomavirus (HPV) testing is to replace cytological
screening by 2019–2020. We conducted a model-based economic evaluation to project the …

Background Cervical cancer is a major concern to women's health, being the fourth most
common cancer worldwide. A great percentage of these cancer is consequence of an HPV …

Objective We aim to compare the cost‐effectiveness of the old cytology programme with the
new high‐risk human papillomavirus (hrHPV) screening programme, using performance …

Objective To report a modelling study using local health care costs and epidemiological
inputs from a population-based program to access the cost-effectiveness of adopting hrHPV …

Objectives To compare both economic and clinical impact of alternative cervical cancer (CC)
screening strategies for women 25-65 years old using different algorithms with primary …

Abstract Objective Eastern European countries are contemplating to introduce the high-risk
Human Papillomavirus (HPV)-test as the primary screening test for their cervical cancer …